Drug Formulary Committee: Minutes of April 19, 2016 Public Meeting

Members in attendance
Al Heaton, RPh, Stuart Williams, J.D., Kathryn Lombardo, M.D., Kelly Ruby, Pharm.D., William Korchik, M.D., Margaret Artz, RPh, Ph.D., Michael Sprehe, M.D.

Members absent:
James Phillips, M.D., Monica Brands, R.Ph., Stacey Ness, Pharm.D.

DHS staff present
Sara Drake, RPh., MPH, MBA, Dave Hoang, Pharm.D., MBA

Others in attendance
Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair
No updates

Approval of the minutes
Minutes from the March 11 and September 22, 2015 and January 19, 2016 meetings were reviewed and approved

New Business

Pharmacy Program Overview - 2015
DHS Pharmacy Program 2015 Overview was presented by the Deputy Director of DHS’ Health Care Purchasing & Service Delivery

Class Review: Sodium glucose co-transporter 2 (SGLT2) inhibitors: Invokana (Janssen), Farxiga (Astra Zeneca), Jardiance (Boehringer Ingelheim)
The committee discussed Invokana (Janssen), Farxiga (Astra Zeneca), Jardiance (Boehringer Ingelheim). The committee recommended to the department by a unanimous vote that Invokana, Farxiga and Jardiance remain on PA. The committee also recommended that in the event of a preferred drug list strategy being pursued for this class, at least one agent with sufficient cardiovascular outcome evidence be available to those high-risk recipients that might benefit from cardiovascular outcome.

New Specialty Drugs for Continued PA
The committee discussed Nucala (GSK) and recommended to the department that Nucala remain on PA by a unanimous vote. The committee recommended the department by a unanimous vote that the department established PA criteria that is more specific and measureable than originally proposed by the department.

The committee discussed Farydak (Novartis) and recommended to the department by a unanimous vote that Farydak remain on PA.

The committee discussed Ninlaro (Takeda). The committee recommended to the department by a unanimous vote that Ninlaro remain on PA.
The committee discussed Lonsurf (Taiho) and recommended to the department by a unanimous vote that Lonsurf remain on PA.

The committee discussed Ibrance (Pfizer) and recommended to the department by a unanimous vote that Ibrance remain on PA.

The committee discussed Iressa (AstraZeneca) and recommended to the department by a unanimous vote that Iressa remain on PA.

The committee discussed Alecensa (Genentech) and recommended to the department by a unanimous vote that Alecensa remain on PA.

The committee discussed Tagrisso (AstraZeneca) and recommended to the department by a unanimous vote that remain on PA.

The committee discussed Cotellic (Genentech) and recommended to the department by a unanimous vote that Cotellic remain on PA.

**Existing Drugs for New PA**
The committee discuss methamphetamine (Desoxyn; Recordati Rare Diseases, Inc.) and recommended to the department by a unanimous vote that Desoxyn require a PA; and PA criteria should require trial of all other existing treatment options for ADHD.

**Existing Drugs for Continued PA**
The committee discussed Viberzi (Allergan) and recommended to the department by a unanimous vote that Viberzi remains on PA.

**Discussion on existing PA criteria:**

**Antiepileptic drugs:**
The committee discussed antiepileptic drugs and existing PA criteria for selected drugs within this class. The committee asked the department to bring additional clinical information and other states’ policies regarding antiepileptic drugs.

**Discussion on Existing Specialty Drugs:**
The committee discussed Invega Trinza (Desoxyn; Recordati Rare Diseases, Inc.) and recommended to the department by a unanimous vote that Invega Trinza be included in the Preferred Drug List and be required to through PA criteria according to FDA-approved label.

**Existing Specialty Drug for New PA:**
The committee discuss EpiPen & EpiPen Jr. (Mylan Specialty) and recommended to the department by a majority vote (one member abstained) that EpiPen require PA for recipients ages 21 and over.

**Adjournment**
The meeting was adjourned at 9:30 pm Central Time.